GLAND logo

Gland Pharma Limited

GLAND·NSE·
₹3,043.20▼ -23.10 (-0.75%)
Market Cap50216.10 Cr
PE Ratio48.81
Volume1,39,656
Day High - Low3096.90 - 3004.30
52W High-Low3171.00 - 1573.60

Gland Pharma Limited (GLAND): company summary

The company's business is improving, with annual revenue rising 14.5% and annual net profit growing 47.0%.

Gland Pharma Limited (GLAND) is a mid-cap Healthcare company valued at ₹50,216 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move
Gland Pharma Limited last traded at ₹3,043.2, modestly down 0.75% on the day.
Recent developments
On 2026-10-01, Gland Pharma announced a $21 million investment in a US drugmaker, acquiring a 60% stake in a newly incorporated entity. On 2026-09-15, the board approved the acquisition of Gland Pharma USA, making it a wholly-owned subsidiary. On 2026-09-05, Fosun Pharma sold a 4.5% stake for ₹2,121 crore. On 2026-09-04, Fosun Pharma divested a 6% stake worth ₹2,800 crore via a block deal, reducing its holding to 45.77%.
Financial performance
The company's business is improving, with annual revenue rising 14.5% and annual net profit growing 47.0%. The latest quarter saw revenue increase 19.5% compared to the same quarter a year earlier, while net profit surged 47.4%, outpacing revenue growth. The net profit margin expanded 3.5 percentage points to 16.0%, and return on capital employed improved to 14.1%.
Valuation multiples
The stock trades at 48.8 times earnings, a premium to the Healthcare median of 32.0, 4.70 times book value. It yields 0.7%.
Things to watch
The stock is 3.4% below its 52-week high. Domestic institutional holding fell 2.91 percentage points in the quarter. Promoter holding decreased by 0.06 percentage points. The company's profit growth slowed to 0.6% over five years, compared to a 9.6% three-year growth rate.
Where it stands
Gland Pharma's revenue and profit have grown significantly, with the latest quarter showing strong gains. The company's net profit margin has expanded, and its return on capital employed is healthy. However, the stock is trading below its 52-week high, and promoter holding has slightly declined. The most significant movement is the recent stake sale by Fosun Pharma, which reduced its holding to 45.77%.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score
5.2/10
Weak
Fair Value
Sign in to see
ROE
9.92%
Average
P/E
48.81x
Expensive
Debt / Equity
0.03
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed

Price performance

NIFTY 500NIFTY SMALLCAP 250NIFTY PHARMA
Day₹3004
₹3097
52W₹1574
₹3171
DocStoX take

Supported by risk (9.5) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 9.5, but that is offset by valuation at 0.0 and growth at 2.6. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence
5.2
/10
Weak
Quality
Solid
ROE 9.9%
Valuation
Expensive
P/E 48.8×
Growth
Flat
Revenue +13.2% 5Y CAGR
Risk
Low risk
D/E 0.03
Momentum
Strong
92% of 52-week range

At a glance

Market Cap
₹50,216 Cr
52W High / Low
₹3171 / ₹1574
Dividend Yield
0.68%
Promoter Holding
45.75%
EPS (TTM)
₹62.35
Book Value
₹628.67

Key highlights

  • Low leverage — D/E 0.03
  • Profitable in all of the last 5 years
  • Healthy net margin (16%)
  • Valuation is weak (0.0/10)
3 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Gland Pharma Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Gland Pharma Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited

Compare Gland Pharma Limited with peers

Gland Pharma Limited vs Sun Pharmaceutical Industries LimitedGland Pharma Limited vs Divi's Laboratories LimitedGland Pharma Limited vs Torrent Pharmaceuticals LimitedGland Pharma Limited vs Apollo Hospitals Enterprise LimitedGland Pharma Limited vs Zydus Lifesciences LimitedGland Pharma Limited vs Laurus Labs Limited

Related tools & concepts

Value Gland Pharma Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing

Explore further

GLAND newsLatest coverage & filingsOpen screenerFilter the whole market
Gland Pharma Limited (GLAND) Share Price & Financials | NSE | DocStoX